EUVIMEDEUVIMED entdecken
Crossref

Enhancing Accuracy of Newborn Screening for 21OHD: Strategic Use of 21-Deoxycortisol in a Large-Scale Tokyo Cohort

Haruki Yamano iD, Kazuhiro Watanabe, Minami Komatsu, Atsuko Hashimoto, Yuri Suzuki, Shizuka Kirino iD, Yoko Saito iD, Eriko Adachi iD, Gau Maki iD, Hisae Nakatani iD, Atsumi Tsuji-Hosokawa iD, Kenichi Kashimada iD und 2 weitere

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgaf506 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Haruki Yamano und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Developmental Biology, Institute of Science Tokyo School of Medicine, Bunkyo-ku, Tokyo 113-8510, Japan. Hauptthemen laut MEDLINE: Neonatal Screening, Adrenal Hyperplasia, Congenital, Cortodoxone. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Newborn screening (NBS) for 21-hydroxylase deficiency (21OHD) has historically shown high false-positive (FP) rates, especially in low-birth-weight (LBW) infants. In 2022, we proposed a second-tier liquid chromatography–tandem mass spectrometry (LC-MS/MS)–based algorithm to improve screening specificity; however, its real-world performance remains unassessed prospectively.

Objective

This work aimed to prospectively evaluate our LC-MS/MS–based screening algorithm for 21OHD and develop a refined version addressing newly identified clinical limitations.

Methods

We prospectively analyzed 326 006 newborns screened in Tokyo from 2021 to 2025. Based on the findings, a revised algorithm was retrospectively validated in 946 246 newborns screened between 2015 and 2025.

Results

The original algorithm showed 100% sensitivity but lower-than-expected positive predictive values (PPVs) (9.0% for initial positives; 44.8% for final referrals). This was mainly due to FPs in LBW infants, who made up 75.7% of initial positives despite being unaffected. Steroid profiling showed elevated 21-deoxycortisol (21DOC) in all true positives but undetectable levels in 99.2% of LBW FPs. A refined algorithm prioritized a low 21DOC cutoff as the primary exclusion criterion, with the 11-deoxycortisol to 17α-hydroxyprogesterone (11DOC/17OHP) ratio as a secondary safeguard. This revision reduced LBW-related recalls by more than 99% and raised PPVs to 87.2% for initial positives and 89.1% for final referrals.

Conclusion

This large-scale prospective study showed that a refined LC-MS/MS algorithm using 21DOC and 11DOC/17OHP greatly improved 21OHD screening specificity, eliminating LBW-related FPs and enhancing NBS efficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neonatal ScreeningAdrenal Hyperplasia, CongenitalCortodoxoneHumansInfant, NewbornAlgorithmsFemaleMaleTokyoTandem Mass SpectrometryProspective StudiesRetrospective StudiesChromatography, LiquidSensitivity and SpecificityInfant, Low Birth WeightBiomarkersCohort StudiesPredictive Value of Tests

Stichwörter der Autor:innen

11-deoxycortisol (11DOC)21-deoxycortisol (21DOC)21-hydroxylase deficiency (21OHD)LC-MS/MSfalse positivesnewborn screening (NBS)

Substanzen

Cortodoxone21-deoxycortisolBiomarkers

Autor:innen und Institutionen

  • Department of Pediatrics and Developmental Biology, Institute of Science Tokyo School of Medicine, Bunkyo-ku, Tokyo 113-8510, Japan.
  • Tokyo Health Service Association, Newborn Screening, Tokyo, Japan.
  • Division of Endocrinology and Metabolism, National Center for Child Health and Development (NCCHD), Setagaya-ku, Tokyo 157-8535, Japan.

ORCID-Profile: Haruki Yamano, Shizuka Kirino, Yoko Saito, Eriko Adachi, Gau Maki, Hisae Nakatani, Atsumi Tsuji-Hosokawa, Kenichi Kashimada, Kei Takasawa

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Yamano, H., Watanabe, K., Komatsu, M., Hashimoto, A., Suzuki, Y., Kirino, S., Saito, Y., Adachi, E., Maki, G., Nakatani, H., Tsuji-Hosokawa, A., Kashimada, K., Ishige, N., & Takasawa, K. (2026). Enhancing Accuracy of Newborn Screening for 21OHD: Strategic Use of 21-Deoxycortisol in a Large-Scale Tokyo Cohort. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf506

Vancouver

Yamano H, Watanabe K, Komatsu M, Hashimoto A, Suzuki Y, Kirino S, et al. Enhancing Accuracy of Newborn Screening for 21OHD: Strategic Use of 21-Deoxycortisol in a Large-Scale Tokyo Cohort. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgaf506

BibTeX
@article{Yamano2026,
  author = {Yamano, Haruki and Watanabe, Kazuhiro and Komatsu, Minami and Hashimoto, Atsuko and Suzuki, Yuri and Kirino, Shizuka and Saito, Yoko and Adachi, Eriko and Maki, Gau and Nakatani, Hisae and Tsuji-Hosokawa, Atsumi and Kashimada, Kenichi and Ishige, Nobuyuki and Takasawa, Kei},
  title = {Enhancing Accuracy of Newborn Screening for 21OHD: Strategic Use of 21-Deoxycortisol in a Large-Scale Tokyo Cohort},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgaf506}
}
Kostenlos starten →